15 March 2021
This inaugural edition of our Corporate Governance Survey of Hong Kong-Listed Biotech Companies marks the third anniversary of the introduction of Chapter 18A to the Hong Kong Stock Exchange’s Listing Rules to facilitate the listings of pre-revenue biotech companies.
The survey is intended to help listed and unlisted companies benchmark themselves against those that have already listed and to provide insights and analysis to stakeholders in the biotech ecosystem.
Click here to read more.
For further information, please contact:
Paloma Wang, Partner, Skadden
paloma.wang@skadden.com
